RevAssist®: A comprehensive risk minimization programme for preventing fetal exposure to lenalidomide

Drug Safety

Volumn 31, Issue 9, 2008, Pages 743-752

  Castaneda, Carmen P ^a   Zeldis, Jerome B ^a   Freeman, John ^a   Quigley, Curtis ^a   Brandenburg, Nancy A ^a   Bwire, Robert ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Lenalidomide, adverse reactions; Pharmaceutical risk management; Postmarketing surveillance; Pregnancy; Prescribing

Indexed keywords

BOSENTAN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ISOTRETINOIN; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TERATOGENIC AGENT;

ADOLESCENT; ADULT; AGED; BEHAVIOR; DEVELOPMENTAL DISORDER; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PHOCOMELIA; PREGNANCY TEST; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK MINIMIZATION PROGRAM; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; UTILIZATION REVIEW; ARTICLE; CONGENITAL MALFORMATION; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; FETUS; METHODOLOGY; PREGNANCY; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ANTINEOPLASTIC AGENTS; FEMALE; FETUS; HUMANS; MALE; MATERNAL EXPOSURE; PATERNAL EXPOSURE; PREGNANCY; RISK MANAGEMENT; TERATOGENS; THALIDOMIDE; UNITED STATES;

EID: 49749133938     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831090-00003     Document Type: Review

References (12)

1. Revlimid [package insert]. Summit (NJ): Celgene Corporation, 2007
2. Christian MS, Laskin OL, Sharper V, et al. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res (Part B) 2007; 80: 188-207
3. FDA. Food and Drug Administration guidance for industry: premarketing risk assessment [online]. Available from URL: http://www.fda.gov/cder/guidance/ 6357fnl.htm [Accessed 2007 Jul 5]
4. FDA. Food and Drug Administration guidance for industry: development and use of risk minimization action plans [online]. Available from URL: http://www.fda.gov/cder/guidance/6358fnl.htm [Accessed 2007 Jul 5]
5. FDA. Food and Drug Administration guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment [online]. Available from URL: http://www.fda.gov/cder/guidance/6359OCC.pdf [Accessed 2007 Jul 5]
6. Uhl K, Trontell A, Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools. Pharmacoepidemiol Drug Saf 2007; 16: 337-48
7. Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21 (2): 319-30
8. Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006; 29 (4): 321-9
9. Segal EA, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European Bosentan Surveillance Programmes. Drug Saf 2005; 28 (11): 971-80
10. Honein M, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens? The iPLEDGE test case. Drug Saf 2007; 30 (1): 5-15
11. Stenman UH, Alfthan H, Ranta T, et al. Serum levels of human chorionic gonadotrophin in nonpregnant women and men are modulated by gonadotrophin- releasing hormone and sex steroids. J Clin Endocrinol Metab 1987; 64: 730-6
12. Snyder J, Haymond S, Parvin C, et al. Diagnostic considerations in the measurement of human chorionic gonadotrophin in aging women. Clin Chem 2005; 51: 1830-5